Side-by-side comparison of AI visibility scores, market position, and capabilities
Raised $130M Series B (Kleiner Perkins) + $45M from Eli Lilly at $1.62B valuation. First demonstrated restoration of youthful killing function in aged human CD8 T cells.
NewLimit is a longevity biotechnology company that demonstrated the first-ever restoration of youthful killing function in aged human CD8 T cells using transcription factor payloads — a major biological milestone with implications for cancer immunotherapy and immune aging. The company raised $130 million in Series B financing led by Kleiner Perkins, followed by $45 million in additional financing from Eli Lilly at a $1.62 billion valuation, with clinical studies in planning.
Web3 authentication and account abstraction infrastructure enabling gasless transactions and simplified dApp onboarding; ERC-4337 implementation allows dApps to sponsor gas fees on behalf of users and accept ERC-20 token gas payment for mainstream-accessible wallet experiences.
Biconomy is a Web3 infrastructure platform focused on making decentralized applications usable by mainstream audiences who are not familiar with cryptocurrency gas mechanics. Its core product implements account abstraction via ERC-4337, allowing dApp developers to sponsor gas fees on behalf of users, accept gas payment in ERC-20 tokens instead of native currency, and batch multiple on-chain transactions into a single user action. These capabilities transform the user experience from one requiring native token balances and technical awareness into something closer to a conventional web application workflow.
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.